David Stiles

572 total citations
8 papers, 453 citations indexed

About

David Stiles is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, David Stiles has authored 8 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Immunology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Epidemiology. Recurrent topics in David Stiles's work include Immune Response and Inflammation (3 papers), Neonatal and Maternal Infections (2 papers) and Cystic Fibrosis Research Advances (2 papers). David Stiles is often cited by papers focused on Immune Response and Inflammation (3 papers), Neonatal and Maternal Infections (2 papers) and Cystic Fibrosis Research Advances (2 papers). David Stiles collaborates with scholars based in United States, Zimbabwe and Canada. David Stiles's co-authors include John P. Pribble, Michael A. Catalano, James W. Mier, Sheldon Wolff, Reuven Porat, Duane C. Bloedow, Charles A. Dinarello, Eric V. Granowitz, S. F. Lowry and Lyle L. Moldawer and has published in prestigious journals such as The Journal of Immunology, The Journal of Clinical Endocrinology & Metabolism and The Journal of Infectious Diseases.

In The Last Decade

David Stiles

7 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Stiles United States	6	166	141	90	60	56	8	453
Víctor Manuel Martínez-Taboada Spain	12	165 1.0×	134 1.0×	69 0.8×	58 1.0×	18 0.3×	17	515
P Gysen Belgium	7	78 0.5×	160 1.1×	98 1.1×	160 2.7×	50 0.9×	13	499
Lorena Álvarez‐Rodríguez Spain	11	66 0.4×	176 1.2×	79 0.9×	57 0.9×	16 0.3×	23	456
Eriko Fujii Japan	13	68 0.4×	97 0.7×	46 0.5×	61 1.0×	19 0.3×	25	462
I Kobayashi Japan	14	59 0.4×	95 0.7×	58 0.6×	66 1.1×	22 0.4×	35	466
Bjoern M. Thobe United States	12	59 0.4×	230 1.6×	90 1.0×	128 2.1×	24 0.4×	13	466
Giuliana Coata Italy	13	39 0.2×	63 0.4×	101 1.1×	60 1.0×	23 0.4×	39	534
Iwona Kucharewicz Poland	11	105 0.6×	72 0.5×	83 0.9×	21 0.3×	103 1.8×	22	499
Akemi Takamizawa Japan	15	254 1.5×	105 0.7×	71 0.8×	150 2.5×	51 0.9×	24	662
Areez Shafqat Saudi Arabia	14	33 0.2×	123 0.9×	132 1.5×	55 0.9×	26 0.5×	45	454

Countries citing papers authored by David Stiles

Since Specialization

Citations

This map shows the geographic impact of David Stiles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Stiles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Stiles more than expected).

Fields of papers citing papers by David Stiles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Stiles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Stiles. The network helps show where David Stiles may publish in the future.

Co-authorship network of co-authors of David Stiles

This figure shows the co-authorship network connecting the top 25 collaborators of David Stiles. A scholar is included among the top collaborators of David Stiles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Stiles. David Stiles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Shrivastava, Anju, Sanjay Singh, David Stiles, et al.. (2025). Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus. Microbiology Spectrum. 13(10). e0149225–e0149225.

McNamara, John, Susanna A. McColley, Gautham Marigowda, et al.. (2019). Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine. 7(4). 325–335. 102 indexed citations

Walker, Seth, Patrick A. Flume, John McNamara, et al.. (2019). A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. Journal of Cystic Fibrosis. 18(5). 708–713. 43 indexed citations

Zee, Kimberly J. Van, S M Coyle, S E Calvano, et al.. (1995). Influence of IL-1 receptor blockade on the human response to endotoxemia.. The Journal of Immunology. 154(3). 1499–1507. 56 indexed citations

Poll, Tom van der, E Fischer, S M Coyle, et al.. (1995). Interleukin-1 Contributes to Increased Concentrations of Soluble Tumor Necrosis Factor Receptor Type I in Sepsis. The Journal of Infectious Diseases. 172(2). 577–580. 8 indexed citations

Poll, Tom van der, Kimberly J. Van Zee, Erik Endert, et al.. (1995). Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man.. The Journal of Clinical Endocrinology & Metabolism. 80(4). 1341–1346. 58 indexed citations

Pribble, John P., Charles G. Fisher, Steven M. Opal, et al.. (1994). HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1ra) INCREASES SURVIVAL TIME IN PATIENTS WITH SEPSIS SYNDROME AND END ORGAN DYSFUNCTION (EOD). Critical Care Medicine. 22(1). A193–A193. 4 indexed citations

Granowitz, Eric V., Reuven Porat, James W. Mier, et al.. (1992). Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 4(5). 353–360. 182 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact